Literature DB >> 2892599

Continuous subcutaneous pump infusion of somatostatin analogue SMS 201-995 versus subcutaneous injection schedule in acromegalic patients.

S E Christensen1, J Weeke, H Orskov, N Møller, A Flyvbjerg, A G Harris, E Lund, J Jørgensen.   

Abstract

Diurnal serum GH patterns were determined in 10 acromegalic patients before treatment, after 3 d continuous s.c. pump infusion and then after 3 d with three equal daily s.c. injections in both instances totalling 100 micrograms/24 h. Subcutaneous injections (33 micrograms) induced impressive suppression of serum GH lasting 3-6 h in eight patients followed by escape to pretreatment values before the next injection. In contrast, continuous infusion resulted in greater and more stable 24 h suppression to the levels reached at the nadir between injections. Suppression of mean 24 h serum GH below 5 ng/ml was achieved by pump treatment in four patients, while two patients had mean values between 5 ng/ml and 10 ng/ml. In four patients occasional or all levels were above 10 ng/ml (24 h average 12.4-102 ng/ml) implying either that adequate suppression by the SMS 201-995, was impossible during the 3 d pump infusion period, or that the dose administered was inadequate. Carbohydrate tolerance was unaffected in either regimen, indicating that reduction in insulin antagonistic hormones balanced inhibition of insulin release. Interestingly, and in contrast to somatostatin, SMS 201-995 did not inhibit TSH release. No untoward effects were observed at the moderate dosage and blood clinical chemistry was unchanged. Fairly constant diurnal serum SMS 201-995 values were obtained during pump infusion, while levels undulated inversely with serum GH during injection treatment. Average diurnal serum somatostatin-C immunoreactivity (all patients) decreased from 496 +/- 129 (mean +/- SD) to 385 +/- 100 ng/ml (P less than 0.003) during pump treatment and did not decrease further during the following 3 d injection treatment (363 +/- 76 ng/ml). The normal adult mean is 179 +/- 40 ng/ml. Computer tomographic (CT) scans of the sellar region were performed in all patients before and after the experimental week. Two patients had extracellular tumours whose size decreased from 8.2 to 4.1 cm3 and from 12.6 to 10.5 cm3. The results demonstrate that superior and stable suppression of GH secretion is obtained during continuous s.c. pump infusion of SMS 201-995.

Entities:  

Mesh:

Substances:

Year:  1987        PMID: 2892599     DOI: 10.1111/j.1365-2265.1987.tb01156.x

Source DB:  PubMed          Journal:  Clin Endocrinol (Oxf)        ISSN: 0300-0664            Impact factor:   3.478


  12 in total

1.  Effect of a new long-acting somatostatin analogue (SMS 201-995) on glycemic and hormonal profiles in insulin-treated type II diabetic patients.

Authors:  R Candrina; G Giustina
Journal:  J Endocrinol Invest       Date:  1988 Jul-Aug       Impact factor: 4.256

Review 2.  Neuroendocrine tumors secreting growth hormone-releasing hormone: Pathophysiological and clinical aspects.

Authors:  Monica Gola; Mauro Doga; Stefania Bonadonna; Gherardo Mazziotti; Pier Paolo Vescovi; Andrea Giustina
Journal:  Pituitary       Date:  2006       Impact factor: 4.107

3.  Reduction in sella turcica volume. An effect of long-term treatment with the somatostatin analogue, SMS 201-995, in acromegalic patients.

Authors:  E Lund; J Jørgensen; S E Christensen; J Weeke; H Orskov; A G Harris
Journal:  Neuroradiology       Date:  1991       Impact factor: 2.804

4.  Cardiovascular effects of a single slow release lanreotide injection in patients with acromegaly and left ventricular hypertrophy.

Authors:  F Manelli; P Desenzani; E Boni; G Bugari; F Negrini; G Romanelli; V Grassi; A Giustina
Journal:  Pituitary       Date:  1999-11       Impact factor: 4.107

Review 5.  Comparison of efficacy and tolerability of somatostatin analogs and other therapies for acromegaly.

Authors:  Morton G Burt; Ken K Y Ho
Journal:  Endocrine       Date:  2003-04       Impact factor: 3.633

6.  Postprandial gall bladder motility and hormone release during intermittent and continuous subcutaneous octreotide treatment in acromegaly.

Authors:  M F Stolk; K J van Erpecum; H P Koppeschaar; W I de Bruin; J B Jansen; C B Lamers; G P van Berge Henegouwen
Journal:  Gut       Date:  1993-06       Impact factor: 23.059

7.  Somatostatin analogue administration prevents increase in kidney somatomedin C and initial renal growth in diabetic and uninephrectomized rats.

Authors:  A Flyvbjerg; J Frystyk; O Thorlacius-Ussing; H Orskov
Journal:  Diabetologia       Date:  1989-04       Impact factor: 10.122

Review 8.  Clinical pharmacokinetics of octreotide. Therapeutic applications in patients with pituitary tumours.

Authors:  P Chanson; J Timsit; A G Harris
Journal:  Clin Pharmacokinet       Date:  1993-11       Impact factor: 6.447

9.  Pharmacokinetic and pharmacodynamic properties of a long-acting formulation of the new somatostatin analogue, lanreotide, in normal healthy volunteers.

Authors:  J M Kuhn; A Legrand; J M Ruiz; R Obach; J De Ronzan; F Thomas
Journal:  Br J Clin Pharmacol       Date:  1994-09       Impact factor: 4.335

10.  Different effects of octreotide by continuous night infusion at increasing rate or by evening injections at different times on morning hyperglycemia and growth hormone levels in insulin-dependent diabetic patients.

Authors:  M Lunetta; M Di Mauro; R Le Moli
Journal:  J Endocrinol Invest       Date:  1998 Jul-Aug       Impact factor: 4.256

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.